Asarina Pharma AB (OSTO:ASAP) YoY EBITDA Growth : 34.94% (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Asarina Pharma AB YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Asarina Pharma AB's YoY EBITDA Growth for the quarter that ended in Dec. 2023 was 34.94%.

Asarina Pharma AB's EBITDA per Share for the six months ended in Dec. 2023 was kr-0.22.

Asarina Pharma AB YoY EBITDA Growth Historical Data

The historical data trend for Asarina Pharma AB's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Asarina Pharma AB YoY EBITDA Growth Chart

Asarina Pharma AB Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

YoY EBITDA Growth

Get a 7-Day Free Trial

-32.93

0.89

55.69

61.54

14.44

Asarina Pharma AB Semi-Annual Data
	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
YoY EBITDA Growth	Get a 7-Day Free Trial									66.21	65.09	56.77	-1.79	34.94

Asarina Pharma AB YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Asarina Pharma AB's YoY EBITDA Growth for the fiscal year that ended in Dec. 2023 is calculated as:

	YoY EBITDA Growth (A: Dec. 2023 )
=	(EBITDA per Share (A: Dec. 2023 )	-	EBITDA per Share (A: Dec. 2022 ))	/	\| EBITDA per Share (A: Dec. 2022 ) \|
=	(-0.616	-	-0.72)	/	\| -0.72 \|
=	14.44 %

Asarina Pharma AB's YoY EBITDA Growth for the quarter that ended in Dec. 2023 is calculated as:

	YoY EBITDA Growth (Q: Dec. 2023 )
=	(EBITDA per Share (Q: Dec. 2023 )	-	EBITDA per Share (Q: Dec. 2022 ))	/	\| EBITDA per Share (Q: Dec. 2022 )) \|
=	(-0.216	-	-0.332)	/	\| -0.332 \|
=	34.94 %

Asarina Pharma AB YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Asarina Pharma AB's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Asarina Pharma AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Asarina Pharma AB (OSTO:ASAP) » Definitions » YoY EBITDA Growth

Comparable Companies

Traded in Other Exchanges

N/A

Address

Fogdevreten 2, Karolinska Institutet Science Park, Solna, SWE, SE-171 65

Website

https://www.asarinapharma.com

Asarina Pharma AB is a Swedish biotech company developing Sepranolone for Allopregnanolone-related stress, compulsion and neurological disorders. Its product pipeline is built on over 40 years of research into llopregnanolone-related neurological disorders. With the new family of GAMSA compounds (GABA-A Modulating Steroid Antagonists) the company aims to deliver a new generation of efficacious and safe drugs for still widely untreated neuroendocrinological conditions.

Asarina Pharma AB Headlines

No Headlines